What Is Paregoric and how is it used?
Paregoric (anhydrous morphine) is a narcotic used to treat diarrhea.
What are side effects of Paregoric?
Common side effects of Paregoric include:
- upset stomach,
- loss of appetite,
- increased sweating, or
- flushing (warmth, redness, or tingly feeling under your skin).
Tell your doctor if you have serious side effects of Paregoric including:
- severe constipation, bloating, stomach cramps;
- urinating less than usual or not at all;
- fast, pounding, or uneven heartbeats;
- feeling like you might pass out;
- weak or shallow breathing; or
- seizures (convulsions).
- PAREGORIC (anhydrous morphine) , USP
- (anhydrous morphine)
Each 5 mL (one teaspoonful) contains:
Anhydrous Morphine (from Opium) .............................................. 2 mg
WARNING: May be habit forming.
Paregoric (anhydrous morphine) is useful for the treatment of diarrhea.
DOSAGE AND ADMINISTRATION
Usual Pediatric Dosage:
0.25 to 0.5 mL/kg of body weight 1 to 4 times a day.
Usual Adult Dosage:
5 to 10 mL (1 to 2 teaspoonfuls) 1 to 4 times a day.
Store at controlled room temperature 59°-86° F (15°-30° C). Protect from light.
NOTE: This product may deposit a sediment if exposed to low temperatures. Filter if necessary.
Dispense in a tight, light-resistant container as defined in the USP
CAUTION: Federal law prohibits dispensing without prescription.
The most frequent adverse reactions include lightheadedness, dizziness, sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down.
DRUG ABUSE AND DEPENDENCE
Paregoric (anhydrous morphine) is a Schedule III narcotic.
Morphine can produce drug dependence and therefore has the potential for being abused. Patients receiving therapeutic dosage regimens of 10 mg every 4 hours for 1 to 2 weeks have exhibited mild withdrawal symptoms. Development of the dependent state is recognizable by an increased tolerance to the analgesic effect and the appearance of purposive phenomena (complaints, pleas, demands, or manipulative actions) shortly before the time of the next scheduled dose. A patient in withdrawal should be treated in a hospital environment. Usually, it is necessary only to provide supportive care with administration of a tranquilizer to suppress anxiety. Severe symptoms of withdrawal may require administration of a replacement narcotic.
Morphine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative/hypnotics or other CNS depressants (including alcohol) has additive depressant effects, and the patient should be so advised. When such combination therapy is contemplated, the dosage of one or both agents should be reduced.
No information provided.
Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal-fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, narcotics produce additional effects that may obscure the clinical course in patients with head injuries.
Special-Risk Patients: Morphine should be given with caution to certain patients, such as the elderly or debilitated and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, and prostatic hypertrophy or urethral stricture.
Morphine should be used with extreme caution in patients with disorders characterized by hypoxia, since even usual therapeutic doses of narcotics may decrease respiratory drive to the point of apnea while simultaneously increasing airway resistance.
Hypotensive Effect: The administration of morphine may result in severe hypotension in the postoperative patient or any individual whose ability to maintain blood pressure has been compromised by a depleted blood volume or the administration of such drugs as the phenothiazines or certain anesthetics.
Supraventricular Tachycardias: Because of a possible vagolytic action that may produce a significant increase in the ventricular response rate, morphine should be used with caution in patients with atrial flutter and other supraventricular tachycardias.
Convulsions: Morphine may aggravate preexisting convulsions in patients with convulsive disorders. If dosage is escalated substantially above recommended levels because of tolerance development, convulsions may occur in individuals without a history of convulsive disorders.
Paregoric (anhydrous morphine) has no known carcinogenic or mutagenic potential. However no longterm animal studies are available to support this observation.
Usage in Pregnancy
Pregnancy Category C: Animal reproduction studies have not been conducted with morphine. It is not known whether morphine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Paregoric (anhydrous morphine) should be given to a pregnant woman only if clearly needed.
Morphine appears in the milk of nursing mothers. Caution should be exercised when paregoric (anhydrous morphine) is administered to a nursing woman.
Signs and Symptoms
Serious overdosage of morphine is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin and sometimes bradycardia and hypotension. In severe overdosage apnea, circulatory collapse, cardiac arrest and death may occur.
Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against the respiratory depression that may result from overdosage or unusual sensitivity to narcotics. Therefore, an appropriate dose of the antagonist should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Since the duration of action of morphine may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration.
Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated.
Hypersensitivity to morphine. Because of its stimulating effect on the spinal cord, morphine should not be used in convulsive states, such as those occurring in status epilepticus, tetanus, and strychnine poisoning.
Morphine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery.
Digestive Disorders Resources
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors